StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.06+0.04 (+3.92%)

Close on Nov 20, 2026Market cap $146.57MP/E –Yield –

ALX Oncology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ALX Oncology's revenue for the twelve months ending Dec 31, 2020 was $1.18M, down 75.4% year over year. For fiscal 2022 it was $0. The highest annual figure on record is $4.80M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$1.18M-75.4%
FY2019Dec 31, 2019$4.80M+132.0%
FY2018Dec 31, 2018$2.07M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$527.00K-59.3%
Q1 FY2020Mar 31, 2020$655.00K–
Q4 FY2019Dec 31, 2019$1.21M–
Q3 FY2019Sep 30, 2019$1.26M–
Q2 FY2019Jun 30, 2019$1.30M–

More ALX Oncology figures

See a number that looks wrong?